Literature DB >> 14998562

Treatment of DCIS--results from clinical trials.

Jack Cuzick1.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 14998562     DOI： 10.1016/j.suronc.2003.09.001

Source DB:  PubMed          Journal:  Surg Oncol        ISSN： 0960-7404            Impact factor:   3.279


× No keyword cloud information.
  11 in total

1.  Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.

Authors:  Aslaug Aamodt Muggerud; Michael Hallett; Hilde Johnsen; Kristine Kleivi; Wenjing Zhou; Simin Tahmasebpoor; Rose-Marie Amini; Johan Botling; Anne-Lise Børresen-Dale; Therese Sørlie; Fredrik Wärnberg
Journal:  Mol Oncol       Date:  2010-06-26       Impact factor: 6.603

Review 2.  The role of radiotherapy in the conservative treatment of ductal carcinoma in situ of the breast.

Authors:  Csaba Polgár; Zsuzsanna Kahán; Zsolt Orosz; Gabriella Gábor; Janaki Hadijev; Gábor Cserni; Janina Kulka; Nóra Jani; Zoltán Sulyok; György Lázár; Gábor Boross; Csaba Diczházi; Eva Szabó; Zsolt László; Zoltán Péntek; Tibor Major; János Fodor
Journal:  Pathol Oncol Res       Date:  2008-04-26       Impact factor: 3.201

3.  Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109.

Authors:  Alexandra Hockla; Derek C Radisky; Evette S Radisky
Journal:  Breast Cancer Res Treat       Date:  2009-12-25       Impact factor: 4.872

4.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Authors:  Jack Cuzick; Ivana Sestak; Sarah E Pinder; Ian O Ellis; Sharon Forsyth; Nigel J Bundred; John F Forbes; Hugh Bishop; Ian S Fentiman; William D George
Journal:  Lancet Oncol       Date:  2010-12-07       Impact factor: 41.316

5.  Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition.

Authors:  Gali Soria; Maya Ofri-Shahak; Ilana Haas; Neora Yaal-Hahoshen; Leonor Leider-Trejo; Tal Leibovich-Rivkin; Polina Weitzenfeld; Tsipi Meshel; Esther Shabtai; Mordechai Gutman; Adit Ben-Baruch
Journal:  BMC Cancer       Date:  2011-04-12       Impact factor: 4.430

6.  Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.

Authors:  Ruria Namba; Lawrence J T Young; Jeannie E Maglione; Erik T McGoldrick; Stephenie Liu; Gregory T Wurz; Michael W DeGregorio; Alexander D Borowsky; Carol L MacLeod; Robert D Cardiff; Jeffrey P Gregg
Journal:  Breast Cancer Res       Date:  2005-09-13       Impact factor: 6.466

7.  PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast.

Authors:  Li Qian; Xiangxiang Gao; Hua Huang; Shumin Lu; Yin Cai; Yu Hua; Yifei Liu; Jianguo Zhang
Journal:  Oncotarget       Date:  2017-03-28

8.  Association of the 12-Gene Breast DCIS Score® Assay With Local Recurrence in Patients With Ductal Carcinoma In Situ Treated on Accelerated Partial Breast Radiotherapy Protocols.

Authors:  Charles E Leonard; Shannon P Tole; Michelle P Turner; John P Bennett; Kathryn T Howell; Dennis L Carter
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

Review 9.  In situ production of sex steroids in human breast carcinoma.

Authors:  Takashi Suzuki; Yasuhiro Miki; Takuya Moriya; Jun-Ichi Akahira; Hisashi Hirakawa; Noriaki Ohuchi; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2007-09-18       Impact factor: 2.070

10.  Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.

Authors:  Zhi-Bin Wan; Hong-Yi Gao; Lian Wei; An-Qin Zhang; Jiang-Yu Zhang; Yi Wang; Dong-Dong Wang; Yan Zhang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.